System-IGF-1 Pathway and Alzheimer's Disease (SIGAL)
Mild Cognitive Impairment
Cognitive Function 1, Social
Control With Normal Activities of Daily Living.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.|
- Circulating IGF-I and IGFBP-3 levels in AD patients and control elderly subjects at the time of assessment(T0). [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- Circulating IGF-I and IGFBP-3 levels [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- Genetic polymorphisms in IGF-I / IGFBP-3 [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- Circulating IGF-I and IGFBP-3 levels and genetic polymorphisms in IGF-I / IGFBP-3 according to cognitive function. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||October 2007|
|Study Completion Date:||July 2012|
|Primary Completion Date:||October 2010 (Final data collection date for primary outcome measure)|
Control elderly subjects with normal cognitive function
AD is the most common cause of dementia. During aging, decline of biological brain functions due to a number of genetic and environmental factors facilitates the onset of AD. MCI includes prodromal AD.
The identification of the risk factors for AD must be a priority in order to define the best therapeutic approach.
Recent data support the notion that IGF-I pathway accounts for neuronal protection, with a dual effect, on both brain Aβ peptide and tau protein.
This large, multicenter, prospective, observational, cross-sectional population-based study in 3 parallel groups (200 participants per group) is aimed to assess differences between IGF-I and IGFBP3 circulating levels and polymorphisms in AD patients and control elderly subjects, and in MCI patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00647478
|Broca Hospital Memory Clinic (CMRR)|
|Paris, France, 75013|
|Principal Investigator:||Olivier Hanon, MD, PhD||Assistance Publique - Hôpitaux de Paris|